Aquestive Therapeutics: Going All-In On AQST-109

Nov. 29, 2022 3:18 AM ETAquestive Therapeutics, Inc. (AQST)7 Comments


  • Aquestive Therapeutics has been making deals to generate cash to help develop their epinephrine candidate, AQST-109. Aquestive appears to be going all-in on AQST-109’s clinical and commercial success.
  • I intend to provide a brief background on AQST-109 and will review the company’s efforts to prioritize its development.
  • I point out some leading downside risks that AQST investors should consider when managing their position. I give AQST a conviction level of 3 out of 5.
  • AQST is still a “Top Idea” in my Compounding Healthcare Seeking Alpha Marketplace Service. I present my plan for adding to my AQST position.
  • I do much more than just articles at Compounding Healthcare: Members get access to model portfolios, regular updates, a chat room, and more. Learn More »

Man"s hands move the winnings casino chips on red table.

kosmos111/iStock via Getty Images

Aquestive Therapeutics (NASDAQ:AQST) has been making moves to maximize the value of the company’s assets in order to generate additional cash that can be used to help with the development of their epinephrine candidate, AQST-109. The

AQST-109 Tmax Vs. EpiPen and IM

AQST-109 Tmax Vs. EpiPen and IM (Aquestive Therapeutics)

AQST-109 Cmax with Repeat vs. EpiPen

AQST-109 Cmax with Repeat vs. EpiPen (Aquestive Therapeutics)

Aquestive Therapeutics Revenue Estimates

Aquestive Therapeutics Revenue Estimates (Aquestive Therapeutics)

Once I have accumulated a suitable position, I am still looking to book profits at my AQST Sell Targets in order to changeover the position to a "House Money" state. If the share price drops back to my Buy Targets, I will recommence accumulating AQST shares and will replicate the method.

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare, and sign up for a free trial.  

This article was written by

Biologics profile picture
Diagnosing the market to compound capital in the healthcare sector.

After years of working in the medical field, I have developed a passion for biotech and lifesaving therapies. Now, I am a full-time healthcare investor who is in search of the next breakthrough therapy, device, or pharmaceutical. My trade focus is around catalysts and potential acquisitions. In addition, I provide a marketplace service, Compounding Healthcare through Seeking Alpha.

Disclosure: I/we have a beneficial long position in the shares of AQST either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (7)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.